Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Expands Study Sites For Seclidemstat Dose Expansion Trial
Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) has announced the addition of Fox Chase Cancer Center in Philadelphia, Pennsylvania, as an active study site for the ongoing clinical trial dose-expansion phase. The company evaluates its flagship candidate, seclidemstat, to treat patients with advanced FET-rearranged and refractory or relapsed Ewing sarcomas. Salarius to evaluate seclidemstat in Ewing sarcoma Fox Chase’s addition expands the participating active trial site number to nine for the open-label…